Drug Type Protein drugs |
Synonyms ML 002, ML002 |
Target |
Action modulators |
Mechanism eOPN3 modulators(extended Opsin 3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Drug Resistant Epilepsy | Preclinical | United States | 01 Dec 2025 | |
| Trigeminal Neuralgia | Preclinical | United States | 17 Nov 2025 | |
| Seizures | Preclinical | United States | 08 Dec 2024 |






